Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc. > Makes sense
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1345)
•••
Comment by CancerSlayeron Jan 03, 2023 3:27pm
167 Views
Post# 35201393

RE:RE:RE:Makes sense

RE:RE:RE:Makes sense

CancerSlayer wrote:

Oilminerdeluxe wrote: Dr. Mandel also notes that the company expects to commence partnering talks with large pharmaceutical companies in 2023 / 2024 to commercialize the technology for BCG-unresponsive NMIBC CIS.

I hope they dont wait for 2024 before talks, he he. So, so tired of waiting. But hopefully, the rewards will soon be here. 

 

I don't see this tech having to wait for your traditional regulatory approval (as was inferred in the article) if 12 month CR percentages maintain/exceed current trends.  Dr. Mandel's public statement that TLT plans to commence partnering talks (beginning in 2023) to commercialize tells me he is optimistic about TLT obtaining an AA this year.  Having that ace in the hole (i.e. an AA vs BTD/Fast Track) would bring much more weight to any partnering talks.  


 

Sorry, I meant AAce in the hole....that was a very positive/telling article.  Thank again Eoganacht for posting.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities